Therapeutics News and Research

RSS

Stealthyx Therapeutics and Cancer Research Technology announce co-development partnership for tumour-targeted therapy

Cancer Research Technology (CRT), the specialist oncology development and commercialisation company, and Stealthyx Therapeutics, the disease targeting drug company spin out of Queen Mary, University of London have entered into an agreement to co-develop Stealthyx’s proprietary drug delivery platform, Prothyx.

16 Feb 2006

Chink in cancer's armor

Much as the famed starship Enterprise would deploy a deflector shield to evade enemy attack, tumor cells are capable of switching on a molecular force field of their own to fend off treatments aimed at killing them. Now University of Florida researchers have found a chink in their armor.

13 Feb 2006

Another step forward in the battle against bacterial infections

Bacterial infections can strike anyone, and they can sometimes be fatal. Because more and more bacteria are becoming resistant to the pre-eminent remedy; antibiotics; the search for new remedies against bacterial infections is in high gear.

12 Feb 2006

Nod1 found to control tumor growth in certain breast cancers

This protein was previously thought to play a role solely in the innate immune system's response to bacterial infection. In the new study, which will be published on-line by the Proceedings of the National Academy of Sciences

12 Feb 2006

Monotherapy phase I clinical trials of novel cytotoxics, targeted therapeutics, antimetastatic agents/angiogenesis inhibitors, and immunotherapeutics/vaccines

Numerous novel oncology agents are currently in phase I monotherapy trials. New Medicine's Oncology KnowledgeBASE (nm|OK) has updated the records of 92 such agents with preclinical or clinical results reported during the 2005 meetings of the American Association for Cancer Research (AACR)

7 Feb 2006

Source of crucial immune cell in the skin discovered - may lead to tumor immunotherapy

Mount Sinai School of Medicine researchers have identified the precursors of cells in the skin that are part of the first line of defense against invading pathogens. The study appears on Nature Immunology's website.

7 Feb 2006

Advance in the fight against bacterial infections

Bacterial infections can strike anyone, and they can sometimes be fatal. Because more and more bacteria are becoming resistant to the pre-eminent remedy - antibiotics - the search for new remedies against bacterial infections is in high gear.

2 Feb 2006

Angina drug finally gets the ok

U.S. regulators have granted approval for the drug Ranexa in the treatment of chronic angina.

31 Jan 2006

New inhaled drug for diabetics an alternative treatment option for some

The Food and Drug Administration (FDA) in the U.S. has given it's approval for the sale of a new drug to treat diabetes.

29 Jan 2006

Study may provide new hope for cancer patients

New study by Mount Sinai researchers may lead to improved stem cell therapies for patients with compromised immune systems due to intensive cancer therapy or autoimmune disease. The study is published in this week's issue of Cell.

27 Jan 2006

New biochip predicts evolution of inflammatory bowel disease

The treatment of inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis, has very high costs and can include admissions and surgical interventions. Until now, there was no precise tools to predict the evolution and prognosis of these diseases.

26 Jan 2006

Sirna Therapeutics awarded patent covering large-scale synthesis of RNAi-based therapeutics

Sirna Therapeutics has announced that the United States Patent and Trademark Office (USPTO) has granted Sirna U.S. Patent No. 6,989,442 for the chemical synthesis and manufacturing of ribonucleic acids (RNA).

25 Jan 2006

First-of-its-kind study in heart attack patients seeks to prevent heart failure with stem cells

University of Rochester Medical Center researchers have announced the launch of a study that will examine whether transplanted stem cells can be safely used to treat damaged heart muscle in patients just after their first heart attack.

23 Jan 2006

Novel compound stops brain cell degeneration in Alzheimer's disease

Drug discovery researchers at Northwestern University have developed a novel orally administered compound specifically targeted to suppress brain cell inflammation and neuron loss associated with Alzheimer's disease.

22 Jan 2006

More monitoring needed for patients taking diuretics

One in five patients taking diuretics commonly prescribed for high blood pressure or heart conditions end up with reduced sodium and potassium levels, according to a study published in the January issue of the British Journal of Clinical Pharmacology.

18 Jan 2006

Coronary artery disease patients consistently fail to take life saving drugs

Nearly half the coronary artery disease (CAD) patients in a seven-year study admitted they don’t consistently take beta blockers, cholesterol-lowering drugs and other medications that could extend their lives, researchers report in Circulation: Journal of the American Heart Association.

10 Jan 2006

Gene discovery may prevent craniofacial birth defects

Craniofacial researchers have developed an animal model that explains how skull malformations occur and how they might be prevented.

22 Dec 2005

Microfluidics chips for simplifying medical imaging biomarkers of disease

A collaboration between scientists at UCLA, Caltech, Stanford, Siemens and Fluidigm have developed a new technology using integrated microfluidics chips for simplifying, lowering the cost and diversifying the types of molecules used to image the biology of disease with the medical imaging technology, Positron Emission Tomography (PET).

15 Dec 2005

MorphoSys signs agreement with Merck

MorphoSys AG announced today that it has signed a five-year license agreement with U.S. pharmaceutical company Merck & Co., Inc. for the use of MorphoSys’s HuCAL GOLD and AutoCAL technologies in research and development of human therapeutic antibodies.

14 Dec 2005

Researchers move in on novel therapeutics to inhibit melanoma

Northwestern University researchers have developed a novel, three-dimensional model that allows scientists to observe how interacting with the microenvironment of metastatic melanoma cells induces normal skin cells to become similar to aggressive cancer cells that migrate and spread throughout the body.

5 Dec 2005